SCHEMBL2946792

SCHEMBL2946792

OCCCCC#Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.48
HTR2B P41595 1/20 0.48
FFAR1 O14842 1/20 0.46
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
PTPN1 P18031 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
GRM5 P41594 4/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.39
CTSK P43235 1/20 0.39
KCNH2 Q12809 1/20 0.39
PTGES O14684 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2951986 0.95 FFAR1 (0.47) HTR2CHTR2BFFAR1CHRNB4CHRNA3
SCHEMBL2950490 0.89 FFAR1 (0.49) FFAR1PTPN1GRM5PTGDR2PTGES
SCHEMBL3936713 0.83 GRM5 (0.45) FFAR1PTPN1ALDH1A1GRM5KCNH2
SCHEMBL1591331 0.82 FFAR1 (0.51) FFAR1PTPN1ALDH1A1GRM5PTGDR2
SCHEMBL7517707 0.81 FFAR1 (0.62) FFAR1PTPN1PTGDR2CTSKPTGES
SCHEMBL2945555 0.81 GABRP (0.43) HTR2CHTR2BFFAR1KDM4EALDH1A1
SCHEMBL3937119 0.80 GRM5 (0.47) HTR2CHTR2BFFAR1PTPN1ALDH1A1
SCHEMBL2236377 0.79 FFAR1 (0.53) FFAR1PTPN1CYP1A2CYP3A4CYP2C19
SCHEMBL31345011 0.79 SHMT1 (0.42) HTR2CHTR2BCHRNB4CHRNA3KDM4E
SCHEMBL2180350 0.78 HTR2C (0.51) HTR2CHTR2BCHRNB4CHRNA3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759370-B2 Sphingosine-1-phosphate (SIP) receptor agonists Praecis Pharmaceuticals (US) 2010-07-20 US disclosed
US-20100009936-A1 CHEMICAL COMPOUNDS PRAECIS PHARMACEUTICALS INCORPORATED (US) 2010-01-14 US disclosed
US-20080096938-A1 Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example PRAECIS PHARMACEUTICALS INCORPORATED (US) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096938-A1 Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example S1PR1, S1PR2, S1PR5 HTR2C 1844/4885HTR2B 1412/4885FFAR1 22/4885
US-20100009936-A1 CHEMICAL COMPOUNDS CD4, ICOS, NFATC1 HTR2C 2437/4885HTR2B 1388/4885FFAR1 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.